Physician profile
John Zafaranloo
NPI 1497720056
$26,204.96
in general payments reported to CMS, 2019-2025
73 companies · $3,812 in 2025
The $3,812 reported for 2025 was more than what 97% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,740 · 2020: $3,193 · 2021: $3,397 · 2022: $3,826 · 2023: $4,435 · 2024: $3,801 · 2025: $3,812.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $12K · Education: $19.62.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $12,028.84 |
| Education | $19.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $4,008.27 | 2019-2025 | Vraylar, Qulipta, Ubrelvy |
| Astrazeneca Pharmaceuticals Lp | $2,820.35 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Novo Nordisk INC | $2,693.02 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Amarin Pharma, INC. | $1,957.30 | 2019-2023 | |
| Lilly USA, LLC | $1,753.20 | 2019-2025 | Mounjaro, Zepbound, Trulicity |
| Kowa Pharmaceuticals America, INC. | $1,351.73 | 2019-2025 | Zoryve, Livalo, Seglentis |
| Takeda Pharmaceuticals U.S.A., INC. | $674.79 | 2019-2025 | Trintellix |
| Pfizer INC. | $647.07 | 2019-2025 | |
| Allergan, INC. | $633.74 | 2019-2020 | |
| Antares Pharma, INC. | $584.82 | 2019-2025 | Xyosted, Nocdurna, Tlando |
| Alkermes, INC. | $581.53 | 2022-2024 | Lybalvi, Aristada, Aristada Initio |
| Amgen INC. | $576.64 | 2019-2025 | Otezla, Repatha, Repatha |
| Sanofi-Aventis U.S. LLC | $564.47 | 2019-2024 | |
| Glaxosmithkline, LLC. | $525.79 | 2019-2024 | Trelegy Ellipta, Arexvy |
| Idorsia Pharmaceuticals US INC | $427.06 | 2022-2025 | Quviviq, Quviviq |
Show all 73 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Zafaranloo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.